NFKB1 and metabolic dysfunction-associated steatotic liver disease: Nonetheless, the activation of Nrf2 is novel therapy to treat NAFLD by upregulating antioxidants, suppressing NF-κB, and regulating the activities of some genes involved in DNL and FA mitochondrial oxidation [18,19].